Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing the stability of a diversified pharmaceutical giant against the high-growth, high-margin profile of a specialized biotechnology pioneer.

Amgen serves a broad patient base across oncology and inflammation, while Vertex focuses on transformative therapies for rare diseases like cystic fibrosis. This comparison evaluates their financials, risk profiles, and valuations to determine which stock offers a more compelling opportunity for retail investors in 2026.

The case for Amgen

Amgen operates as a global biotechnology powerhouse, focusing on serious diseases across oncology, inflammation, and rare disease segments. A concentrated wholesaler network, including McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH), accounted for nearly 77% of worldwide gross revenues in 2025. Customer concentration like this adds a layer of risk to the business, though it is common among large biotech stocks. Amgen markets its portfolio through internal sales forces and strategic collaborations with partners such as Astellas Pharma (OTC:ALPMF), Takeda Pharmaceutical (NYSE:TAK), and Kyowa Kirin (OTC:KYKOF).

In FY 2025, revenue reached nearly $36.7 billion, representing a roughly 9.9% increase from the prior year. This growth helped the company generate net income of close to $7.7 billion during the same period. The net margin, which measures how much of each dollar of revenue remains as profit after all expenses, stood at approximately 21%. This result was a significant improvement over the prior fiscal year, reflecting the company's ability to scale its diverse drug portfolio efficiently.

As of its December 2025 balance sheet, the debt-to-equity ratio was approximately 6.3x. This ratio compares total debt to the amount shareholders have invested, with Amgen's level indicating a reliance on borrowed capital. The current ratio, which measures the ability to cover short-term liabilities with short-term assets, was roughly 1.1x. Free cash flow, the cash left over after capital expenditures, reached nearly $8.1 billion in FY 2025, providing ample funds for dividends and further research.

The case for Vertex Pharmaceuticals

Vertex Pharmaceuticals has built a dominant position in the treatment of cystic fibrosis, providing life-saving medicines to patients worldwide. The company is currently expanding into new areas like sickle cell disease through its gene therapy, CASGEVY, which it developed with CRISPR Therapeutics (NASDAQ:CRSP). Vertex sells its products primarily to specialty pharmacies and major wholesalers, maintaining a high level of control over its specialized market. Its focus on high-need, rare diseases allows for significant pricing power and a relatively loyal customer base.

In FY 2025, revenue reached nearly $12.1 billion, growing close to 9.6% year-over-year. Net income for the year was roughly $4.0 billion. This resulted in a very strong net margin of approximately 32.7%. This high level of profitability is characteristic of the company's focused business model, where a small number of highly effective drugs generate substantial returns on investment.

As of its December 2025 balance sheet, Vertex maintained a very conservative financial position with a debt-to-equity ratio of approximately 0.2x. This indicates that the company has very little debt relative to its equity. Its current ratio was nearly 2.9x, suggesting a high level of liquidity and financial flexibility. Free cash flow for FY 2025 reached close to $3.2 billion, providing the capital necessary to fund an ambitious research and development pipeline without the need for significant borrowing.

Risk profile comparison

Amgen faces significant risks from government and commercial pricing pressures, particularly with Medicare price-setting initiatives. The company also deals with intense competition from biosimilars as patents for key drugs like Prolia and XGEVA expired in 2025. Additionally, its manufacturing is heavily concentrated in specific locations like Puerto Rico and Thousand Oaks, California. This creates exposure to potential supply chain disruptions or natural disasters that could halt production for its global markets.

Vertex Pharmaceuticals is highly dependent on its cystic fibrosis medicines, meaning any safety or reimbursement issues in that single area could severely impact the company. The business also carries the inherent uncertainty of drug development, recently highlighted by the discontinuation of its VX-264 and VX-993 programs. Furthermore, scaling complex cell and gene therapies presents operational challenges that differ from its traditional pill-based treatments. Pricing pressures and potential changes to healthcare policy also remain constant threats to its high-margin revenue streams.

Valuation comparison

Amgen appears more attractively priced based on its Forward P/E, while Vertex commands a premium valuation that likely reflects its superior margins and clean balance sheet.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with Vertex. Its cystic fibrosis franchise is one of the most dominant in the history of specialty pharma, with Trikafta and Alyftrek now reaching nearly all patients with the disease, and revenue continuing to grow. Beyond that, Casgevy revenue more than doubled year over year. A new pain drug is also gaining traction, and a pending acquisition adds a fifth disease area with a multibillion-dollar opportunity. Management raised its full-year outlook and the balance sheet is flush with cash.

Amgen, to its credit, is a dependable, dividend-paying biotech with multiple brands growing at a double-digit rate. For investors who prioritize steady income alongside growth, it is a solid choice.

But Vertex is growing faster, expanding into more disease areas simultaneously, and doing it with operating margins that most pharmaceutical companies would envy. For a long-term investor interested in the healthcare sector, that combination of a dominant franchise and an expanding pipeline is difficult to match right now.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen and Vertex Pharmaceuticals. The Motley Fool recommends CRISPR Therapeutics and McKesson. The Motley Fool has a disclosure policy.